Pluristem to Release Trial Results - Analyst Blog

By
A A A

Pluristem Therapeutics Inc . ( PSTI ) recently announced that it will release the results of its phase I/II clinical trial, evaluating the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury, on Jan 21, 2014.

Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics ( UTHR ) or through research and clinical institutions.

The cells from placenta are derived using the company's proprietary PluriX therapy and are known as PLacental eXpanded cells. Pluristem's first candidate in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).

We note that Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.

The phase I/II study comprised three treatment groups - two PLX-PAD groups of different doses and one placebo group. The study was initiated in Apr 2013. The primary endpoints of the trial were safety and the maximal contraction force of the gluteal muscle at six months post-surgery while the secondary endpoints included an analysis of the macrostructure and microstructure of the gluteal muscle using magnetic resonance imaging (MRI) and biopsy.

A positive outcome from this study will enable Pluristem to further evaluate the potential of PLX-PAD cells for this indication along with other potential surgical orthopedic injuries and non-surgical sports related injuries. We expect investor focus on results from the trial.

Pluristem currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Forest Laboratories ( FRX ) and Lannett Company, Inc . ( LCI ) with a Zacks Rank #1 (Strong Buy).



FOREST LABS A (FRX): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

PLURISTEM THERA (PSTI): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: FRX , LCI , PSTI , UTHR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

34,599,049
  • $16.961 ▼ 0.52%
28,603,274
  • $13.52 ▼ 4.72%
26,025,383
  • $76.8999 ▼ 2.71%
26,004,204
  • $14.60 ▼ 1.28%
25,058,827
  • $97.85 ▼ 0.95%
21,756,069
  • $25.20 ▲ 0.12%
19,791,510
  • $99.90 ▼ 0.84%
19,391,219
  • $40.7176 ▼ 0.08%
As of 10/1/2014, 11:46 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com